Insurance & Pricing Guide ·
By The RX Index Editorial Team · · Refresh schedule: monthly through 2026, then quarterly
GLP-1 Copay Assistance Programs 2026: What Actually Works by Drug and Insurance Type
Brand-name GLP-1 medications list at $900 to $1,350 per month. But almost nobody should be paying that — and the fact that you’re searching for GLP-1 copay assistance programs in 2026 tells us you already know a cheaper path exists. You just can’t figure out which one actually applies to you.
Here’s the short version: if you have commercial insurance that covers your medication, a manufacturer savings card can drop your cost to $25 per month or less. If you’re on Medicare Part D, a new demonstration program launching July 1, 2026 caps your copay at $50 per month. If you’re uninsured and low-income, patient assistance programs may cover the full cost. And if you fall through every one of those — which happens to more people than the drug companies’ ads suggest — there are licensed telehealth providers with transparent pricing and no prior authorization required.
The problem is that Wegovy, Ozempic, Zepbound, Foundayo, Mounjaro, Rybelsus, and Trulicity all have different rules, different caps, and different catches. No single manufacturer page compares them. We pulled the terms from every official source and flagged every place where the public information conflicts with what’s widely claimed online.
Your Fastest Path: Choose Your Situation
Before you read further, find your row.
| Your situation | First program to check | What you might pay | Biggest catch |
|---|---|---|---|
| Commercial insurance covers your GLP-1 | Manufacturer savings card for your specific drug | As low as $25/mo | Annual savings caps run out mid-year for some patients |
| Commercial insurance but drug NOT covered | Manufacturer self-pay programs (NovoCare Pharmacy, LillyDirect) | $149–$499/mo depending on drug and dose | Intro pricing expires — Wegovy starter doses jump after 2 fills |
| Medicare Part D + obesity indication | Medicare GLP-1 Bridge (starts July 1, 2026) | $50/mo flat | Doesn't count toward your Part D TrOOP or out-of-pocket cap |
| No insurance + low income | Novo Nordisk PAP or Lilly Cares (drug-specific) | $0 if approved | Public product lists are narrower than most articles claim |
| Insured but copay still too high | PAN Foundation obesity fund (when open) | Up to $1,000 in help | Fund opens and closes quickly; your plan must already cover the drug |
| Savings card failed at pharmacy | See troubleshooting section below | Varies | Usually a processing issue, not a permanent block |
What We Actually Verified
- ✅ Manufacturer savings card terms for Wegovy, Ozempic, Zepbound, Foundayo, Mounjaro, Rybelsus, and Trulicity — verified on each official program page between –
- ✅ Novo Nordisk PAP product list — checked the PDF linked from NovoCare’s PAP landing page
- ✅ Lilly Cares application — checked the current PDF application and eligibility page at lillycares.com
- ✅ Medicare GLP-1 Bridge — verified against the official CMS FAQ page, updated
- ✅ PAN Foundation obesity fund — checked panfoundation.org for current status and eligibility
- ⚠️ Anything we couldn’t fully verify from a current public source is marked [NEEDS VERIFICATION]
If a “savings guide” doesn’t tell you what it checked, be skeptical. The internet is full of stale PAP claims — we found several that don’t match current public documents.
The 2026 Verified GLP-1 Assistance Matrix
Assembled from 14 official sources so you can see every legitimate program in one place.
Weight-Management Medications
| Program | Drug | With coverage | Without coverage / self-pay | Gov. plans? | PAP? | Savings limits | Expires | Key catch | Verified |
|---|---|---|---|---|---|---|---|---|---|
| NovoCare Savings | Wegovy (injection) | $25/mo (max $100/mo savings) | $199/mo intro for 0.25/0.5 mg (first 2 fills through 6/30/26), then $349/mo | No | Current PAP product list does NOT show Wegovy | Max $100/mo savings | Annual refresh | Intro pricing only for starter doses, first 2 fills | 4/15/26 |
| NovoCare Savings | Wegovy (pill) | $25/mo (max $100/mo savings) | $149/mo (1.5 mg, 4 mg); $299/mo (9 mg, 25 mg). 4 mg rises to $199 after 8/31/26 | No | See above | Max $100/mo savings | Annual refresh | 4 mg cost jumps Sept. 1; higher oral doses are $299 | 4/15/26 |
| Zepbound Savings | Zepbound (single-dose pen) | $25/mo (max $100/mo savings) | $499/mo for up to 13 fills | No | Lilly Cares does NOT list Zepbound | Covered: $1,300/yr | 12/31/2026 | KwikPen is cheaper for self-pay — ask your doctor about format | 4/15/26 |
| Zepbound Savings | Zepbound (KwikPen) | $25/mo | $299 (2.5 mg), $399 (5 mg), $449 (7.5 mg+) | No | No | Covered: $1,300/yr | 12/31/2026 | Must refill within 45 days on 7.5 mg+ to keep pricing | 4/15/26 |
| Zepbound Self Pay Journey | Zepbound (vial + KwikPen) | N/A — self-pay only | $449/mo for 7.5/10/12.5/15 mg (auto-applied from 2/23/26) | No | No | Purchase-offer pricing | 12/31/2026 | 45-day refill window on higher doses | 4/15/26 |
| Foundayo Savings | Foundayo (oral pill) | $25/mo (max $100/mo savings) | $149 (0.8 mg), $199 (2.5 mg), $299 (5.5 mg+) | No | [NEEDS VERIFICATION] — not confirmed on Lilly Cares | $1,000/yr; 10 fills max | 12/31/2026 | New (April 2026) — most formularies haven't added it. 45-day refill rule on 14.5/17.2 mg only. | 4/15/26 |
Diabetes Medications (People Also Search in This Cluster)
| Program | Drug | With coverage | Without coverage | Gov. plans? | PAP? | Savings limits | Expires | Key catch | Verified |
|---|---|---|---|---|---|---|---|---|---|
| NovoCare Savings | Ozempic | $25/mo (max $100/mo, up to 48 months) | $199/mo intro for 0.25/0.5 mg (2 fills through 6/30/26), then $349 (≤1 mg) or $499 (2 mg) | No | Yes — PAP list shows Ozempic (≤200% FPL). Medicare Part D patients with coverage no longer eligible. | Max $100/mo, up to 48 mo | Ongoing | Off-label weight-loss Rx less likely to get insurance coverage | 4/15/26 |
| Mounjaro Savings | Mounjaro | $25/mo (max $150/mo savings) | $499/mo (max $647/mo savings) | No | Lilly Cares does NOT list Mounjaro | Covered: $1,950/yr. Non-covered: $8,411/yr. 13 fills max. | 12/31/2026 | FDA-approved for type 2 diabetes only — Lilly states: "Mounjaro is not a weight loss drug" | 4/15/26 |
| NovoCare Savings | Rybelsus | $25/mo. 3 mg: max $100 savings, 1-month fills only. 7/14 mg: up to $300 savings on 3-mo fills, up to 48 months. | Varies | No | [NEEDS VERIFICATION] — PAP list does NOT show Rybelsus | See terms by dose | Annual refresh | Stale PAP claims circulate widely — verify before applying | 4/15/26 |
| Trulicity Savings | Trulicity | $25/mo | Varies | No | Yes — Lilly Cares lists Trulicity (Group 1, ≤300% FPL ≈ $47,880/individual). New applications accepted. | $1,950/yr; 13 fills max | 12/31/2026 | One of the few GLP-1s still on Lilly Cares | 4/15/26 |
Non-Manufacturer Programs
| Program | Eligible drugs | Cost | Who qualifies | Key catch | Verified |
|---|---|---|---|---|---|
| Medicare GLP-1 Bridge | Wegovy (injection + pill), Zepbound KwikPen, Foundayo | $50/mo flat | Part D enrollees (PDP or MA-PD) meeting BMI/clinical criteria — see Medicare section below | $50 does NOT count toward TrOOP. No coupon stacking. Zepbound pen/vial excluded. | CMS.gov 4/15/26 |
| PAN Foundation Obesity Fund | Plan must already cover the medication | Up to $1,000 | U.S. residents with insurance, ≤300% FPL, qualifying medication on PAN list | Fund opens/closes rapidly. Not a no-insurance solution. | PAN Foundation 4/15/26 |
GLP-1 Copay Assistance Programs: How Savings Cards Work (and the Cap That Bites)
If your commercial insurance plan covers your GLP-1, a manufacturer savings card is almost certainly your cheapest option. Every major brand offers one, and they all work the same way: your insurance processes the claim first, the savings card covers most or all of the remaining copay. In practice, that means $25 per month or less for most commercially insured patients with coverage.
How to Activate Your Savings Card
Novo Nordisk drugs (Wegovy, Ozempic, Rybelsus): Visit NovoCare.com or text SAVE to 83757. You’ll get a digital card with BIN, PCN, Group, and Member ID numbers. Present at the pharmacy with your insurance card. Takes about 3 minutes.
Eli Lilly drugs (Zepbound, Foundayo, Mounjaro, Trulicity): Visit each drug’s official savings page or call 1-800-545-5979.
The Annual Cap Problem
Every card has savings limits. Here’s what that means in practice: Zepbound with insurance coverage saves up to $100/month, capped at $1,300/year. If your copay is $125, you pay $25 — great. But if your copay is $400 (common on specialty tiers), the card saves $100 and you still owe $300. You’ll exhaust the annual cap by fill 13. Know the math before you start.
FEHB and ACA Exchange Plans
FEHB plans and ACA marketplace plans are not classified as government plans for savings card purposes under Novo Nordisk’s current eligibility terms. FEHB members may be eligible even though they work for the federal government. Verify drug by drug before enrolling.
Official savings pages
What If Your Insurance Doesn’t Cover Your GLP-1?
If your commercial plan excludes your GLP-1, the savings card still provides some discount, but instead of $25/month you’re looking at $149 to $499 depending on drug and dose.
Wegovy Self-Pay (NovoCare Pharmacy)
| Formulation | Dose | Monthly price | Notes |
|---|---|---|---|
| Injection | 0.25 mg, 0.5 mg | $199/mo | Intro offer, first 2 fills only through 6/30/26 |
| Injection | Maintenance doses | $349/mo | Standard self-pay rate |
| Pill | 1.5 mg | $149/mo | — |
| Pill | 4 mg | $149/mo | Rises to $199 after 8/31/26 |
| Pill | 9 mg, 25 mg | $299/mo | — |
⚠️ Plan for the step-up. If $349/month for injection maintenance isn’t sustainable, have a backup ready before your starter fills run out.
Zepbound Self-Pay: Format Matters
| Format | Dose | Monthly price |
|---|---|---|
| Single-dose pen (non-covered) | Any dose | $499/mo |
| KwikPen | 2.5 mg | $299/mo |
| KwikPen | 5 mg | $399/mo |
| KwikPen | 7.5 mg+ | $449/mo |
| Single-dose vial (Self Pay Journey) | 7.5/10/12.5/15 mg | $449/mo |
💡 Up to $200/month difference depending on format. Ask your prescriber about the KwikPen or vial if you’re self-paying.
⚠️ 45-day refill rule: For KwikPen and vial doses 7.5 mg and above, you must refill within 45 days of your previous delivery to keep purchase-offer pricing. Set a calendar reminder.
Foundayo Self-Pay (LillyDirect) — Most Affordable Brand-Name Entry Point in 2026
| Dose | Monthly price | Notes |
|---|---|---|
| 0.8 mg (starter) | $149/mo | — |
| 2.5 mg | $199/mo | — |
| 5.5 mg+ (maintenance) | $299/mo | 45-day refill rule on 14.5/17.2 mg only |
Daily pill, no injection, no fasting requirements. Shipping through LillyDirect began .
When to appeal instead of self-paying
If your plan denied coverage, appeal with proper documentation — BMI history, comorbidities, prior lifestyle interventions, and where applicable, a cardiovascular risk reduction indication for Wegovy. This may be faster and cheaper than months of self-pay. See our GLP-1 insurance prior authorization guide →
Can You Use GLP-1 Savings Cards with Medicare, Medicaid, VA, or TRICARE?
Usually, no. Manufacturer savings cards for the GLP-1s reviewed here exclude government beneficiaries, driven by federal anti-kickback restrictions. But Medicare Part D now has a separate 2026 route through the Medicare GLP-1 Bridge.
The Medicare GLP-1 Bridge: Who Qualifies
The Bridge is a short-term CMS demonstration running July 1 through December 31, 2026, operating outside the standard Part D benefit.
Eligible plan types
Standalone PDP, MA-PD coordinated care plans (HMO, HMOPOS, Local and Regional PPO), including qualifying SNPs, EGWPs, and dually eligible beneficiaries in those plan types.
Clinical criteria — you must meet one of three tiers:
| Tier | BMI requirement | Plus diagnosis of |
|---|---|---|
| 1 | ≥35 at therapy initiation | No additional diagnosis required |
| 2 | ≥30 at therapy initiation | Heart failure with preserved ejection fraction (HFpEF), OR uncontrolled hypertension on two or more antihypertensives, OR chronic kidney disease stage 3a+ |
| 3 | ≥27 at therapy initiation | Pre-diabetes (per ADA guidelines), OR previous myocardial infarction, OR previous stroke, OR symptomatic peripheral artery disease |
Eligible medications: Foundayo (all formulations), Wegovy injection, Wegovy tablets, and Zepbound KwikPen. Zepbound single-dose pen and single-dose vial are not eligible.
Cost: $50/month flat copay
What the Bridge does NOT do
- ❌ The $50 copay does not count toward TrOOP (True Out-of-Pocket spending) or the Part D $2,100 annual out-of-pocket cap
- ❌ Manufacturer coupons and discount programs cannot be applied to Bridge claims
- ❌ CMS administers it centrally (Humana/LI NET), not through your Part D plan
- ❌ It’s temporary — ends December 31, 2026. Continuing in 2027 requires a Part D plan that joins the BALANCE Model
Before July: What Medicare Patients Can Do Now
- ✅ Ozempic and Mounjaro are already covered under Part D for type 2 diabetes
- ✅ Wegovy may be covered for CV risk reduction with documented cardiovascular disease
- ✅ LillyDirect and NovoCare Pharmacy offer self-pay pricing — Foundayo at $149/month is the most affordable brand-name option
- ✅ Talk to your prescriber now so PA paperwork is ready for July 1
Important context: Some GLP-1 uses are already covered under the basic Part D benefit. Wegovy for cardiovascular risk reduction and Zepbound for obstructive sleep apnea are Part D-coverable indications — those go through your Part D plan, not the Bridge. The Bridge covers GLP-1s prescribed specifically for weight reduction.
Ro checks insurance coverage and handles PA — free coverage check →Which GLP-1 Patient Assistance Programs Still Offer Free Medication in 2026?
Both Novo Nordisk and Eli Lilly run patient assistance programs providing medications at no cost. But the public 2026 product lists are narrower than the internet suggests.
Novo Nordisk PAP
Ozempic PAP eligibility:
- ✅ Uninsured or Medicare without Part D drug coverage
- ❌ Commercially insured — NOT eligible
- ✅ Income ≤200% FPL
- ❌ Not enrolled in Medicaid, full LIS, or VA benefits
- ⚠️ New for 2026: Medicare Part D patients with drug coverage no longer eligible
Processing: complete applications processed within 2 business days; approved medication ships within 5 business days. Enrollment lasts 12 months (uninsured) or the calendar year (Medicare). Reapplication required at enrollment end.
Lilly Cares Foundation
Trulicity PAP eligibility (Group 1):
- ✅ Uninsured or Medicare Part D
- ✅ Income ≤300% FPL (~$47,880 for a 1-person household)
- ❌ Not enrolled in Medicaid, full LIS, or VA
Apply at lillycares.com or call 1-800-545-6962.
The stale-internet problem
A significant number of online articles reference PAP coverage for drugs we cannot verify from current manufacturer documents. Rybelsus, Wegovy, Mounjaro, and Zepbound PAP claims are especially common — and especially hard to confirm against 2026 materials. Before you spend time on an application, check the current product list on the official program page.
The PAN Foundation: Charity Help for GLP-1 Copays
Up to $1,000 in copay assistance
Eligibility: Insured (plan must cover the drug), U.S. resident, income ≤300% FPL, qualifying medication on PAN’s list.
The Copay Accumulator Trap: Is Your Insurer Clawing Back Your Savings?
A copay accumulator prevents your savings card payments from counting toward your annual deductible or out-of-pocket maximum. Your card burns through its cap while your deductible sits untouched. Once the card runs dry, you owe the full copay with zero deductible progress.
43% of commercially insured covered lives are enrolled in plans with copay accumulators
Source: IQVIA, “Still on the Rise: Deductible Accumulators & Copay Maximizers in 2024,” April 2025.
How to Check
Call the number on your insurance card. Ask: (1) “Does my plan have a copay accumulator or maximizer?” and (2) “Will manufacturer copay assistance count toward my deductible and out-of-pocket maximum?”
States That Have Banned Accumulators
25 states plus D.C. and Puerto Rico have enacted bans in state-regulated plans, affecting at least 16.8% of U.S. commercial lives (~34 million people). (Source: Avalere Health Advisory, December 2025.)
What to Do in an Accumulator Plan
- Budget for the cliff — calculate when your annual cap runs out based on your actual copay
- Front-load fills via 90-day mail-order if allowed
- Compare total annual cost of insurance + savings card vs. self-pay through LillyDirect/NovoCare — in accumulator plans, self-pay sometimes wins over a full year
HSA and FSA: Paying with Pre-Tax Dollars
GLP-1 medications are eligible for HSA and FSA payments when prescribed for a diagnosed medical condition such as obesity or type 2 diabetes. Because these accounts use pre-tax income, you effectively reduce your cost by your marginal tax rate. HSA/FSA can be combined with manufacturer savings cards — use both when possible.
The Savings Card Didn’t Work at the Pharmacy
A brand-specific rejection map based on the most common failure points in official program terms:
| Rejection cause | Which drugs | Fix |
|---|---|---|
| Government insurance detected | All brands | Any government coverage — even secondary — triggers auto-reject. No workaround. |
| Wrong product form | Zepbound (pen vs. KwikPen vs. vial have separate terms) | Confirm pharmacy dispensed the exact form your card covers. |
| Card as primary, not secondary | All brands | Ask pharmacist to process insurance first, then savings card via coordination of benefits. |
| Incorrect BIN/PCN | All brands | Double-check every digit against your digital card. |
| AFP exclusion | All brands | Both Novo and Lilly exclude patients routed through an alternate funding program. Check with HR. |
| 45-day refill expired | Zepbound KwikPen/vial 7.5 mg+; Foundayo 14.5/17.2 mg | Refill within 45 days of previous delivery. |
Support lines: NovoCare: 1-888-793-1218 · Eli Lilly: 1-800-545-5979
What If None of These Assistance Programs Fit?
There is no universal GLP-1 coupon in 2026. If you have government insurance and don’t qualify for the Bridge, the wrong formulation, an AFP, income above PAP thresholds, or a plan that excludes weight management — a real number of people land in a gap where none of the official programs above fully solve the problem. The $25/month in the ads is real, but it has eligibility requirements that exclude millions of people.
But “excluded from official programs” does not mean “no options.” The path forward looks different.
Appeal the denial
Our prior authorization guide walks through BMI documentation, comorbidities, lifestyle interventions, and the cardiovascular risk reduction indication for Wegovy.
See our GLP-1 prior authorization guide →Ask about a covered alternative
If your plan covers Ozempic or Mounjaro for diabetes and you qualify, your doctor can prescribe a covered medication. Wegovy may be covered for CV risk reduction with documented CVD.
Use a brand-name direct self-pay path
Foundayo at $149/month (LillyDirect) is the most affordable brand-name entry point. NovoCare Pharmacy offers Wegovy pill from $149/month.
Consider a telehealth provider that handles access for you
If you've exhausted every path above, several licensed providers offer GLP-1 programs at different price points.
We earn a commission if you sign up through our links — that’s how we fund this research. We only include providers verified for licensing, pharmacy sourcing, and independent patient reviews.
Important: The providers below use different medication pathways. Ro prescribes FDA-approved brand-name medications — their membership fee ($39 first month, then $149/month or as low as $74/month with annual plan) is separate from medication cost. Eden, MEDVi, and SHED offer programs that include compounded GLP-1 medications. Compounded medications are prepared by licensed pharmacies based on individual prescriptions but are not FDA-approved and have not been evaluated by the FDA for safety, efficacy, or quality.
Eden
Trustpilot 4.4/5 · 3,390+ reviews · 100K+ members
Same price at every dose — your cost doesn’t increase as your dose goes up.
Check eligibility with Eden →MEDVi
Trustpilot 4.4/5 · 12,159+ reviews · LegitScript-certified
Deepest independent review footprint in telehealth GLP-1.
See MEDVi pricing →SHED
Trustpilot 4.6/5 · 863+ reviews
Multiple formats including non-injection options and a 10% weight-loss money-back guarantee.
See SHED’s options →Ro
FDA-approved Zepbound® and Foundayo™ · Starts at $39/month
Membership starts at $39/month. Medication cost is additional and varies by drug, insurance, and savings card status. Insurance concierge handles PA and appeals.
Check Ro eligibility →How We Verified This Page
| Source | What we checked |
|---|---|
| NovoCare.com | Wegovy, Ozempic, Rybelsus savings terms; PAP eligibility + product list PDF |
| Zepbound.lilly.com | Savings card, KwikPen, vial, Self Pay Journey terms |
| Foundayo.lilly.com | Savings card terms, LillyDirect pricing |
| Mounjaro.lilly.com | Savings card terms: covered ($150/mo, $1,950/yr) and non-covered ($647/mo, $8,411/yr) |
| Trulicity.lilly.com | Savings card terms |
| LillyCares.com | PAP application PDF, eligibility, medication list |
| CMS.gov | Medicare GLP-1 Bridge FAQ (updated 4/6/26) — eligibility tiers, eligible drugs, cost treatment |
| PAN Foundation | Obesity copay fund eligibility |
| Avalere Health | Copay accumulator state bans (Dec 2025 analysis) |
| IQVIA | Accumulator prevalence (April 2025 analysis) |
Refresh schedule: monthly through 2026, then quarterly.
Frequently Asked Questions
Are GLP-1 savings cards only for commercial insurance?
Yes. Every manufacturer savings card reviewed here — Wegovy, Ozempic, Zepbound, Foundayo, Mounjaro, Rybelsus, and Trulicity — excludes government insurance beneficiaries including Medicare, Medicaid, VA, and TRICARE.
Can I use a GLP-1 savings card with Medicare?
No. The Medicare GLP-1 Bridge launching July 1, 2026 offers a $50 per month copay for qualifying Part D beneficiaries. It covers Wegovy (injection and pill), Zepbound KwikPen, and Foundayo.
What is the Medicare GLP-1 Bridge?
A short-term CMS demonstration running July 1 through December 31, 2026 providing eligible Medicare Part D beneficiaries access to select GLP-1 medications for weight loss at a $50 per month copay, bridging to the BALANCE Model in January 2027.
Which GLP-1 drugs still have patient assistance programs in 2026?
Per current public documents: Ozempic is on Novo Nordisk's PAP list (income at or below 200% FPL). Trulicity is on Lilly Cares (Group 1, at or below 300% FPL / approximately $47,880 for a 1-person household). Wegovy, Mounjaro, Zepbound, and Foundayo could not be confirmed on current public PAP product lists as of April 2026.
Does self-pay through NovoCare or LillyDirect count toward my deductible?
No. Both manufacturers state that self-pay purchases outside of insurance do not count toward deductibles or out-of-pocket maximums.
Can FEHB members use manufacturer savings cards?
Novo Nordisk's current terms do not classify FEHB as a government program for savings card purposes. FEHB members with commercial-style coverage may be eligible. Verify with each manufacturer before enrolling.
Can a charity help with GLP-1 obesity treatment copays?
PAN Foundation's obesity copay fund provides up to $1,000 for eligible insured patients whose plan covers the medication and whose income is at or below 300% FPL. Fund availability changes without warning — check panfoundation.org for current status.
What if my insurance plan has a copay accumulator?
A copay accumulator prevents savings card payments from counting toward your deductible. Per IQVIA, 43% of commercial covered lives are affected. 25 states plus D.C. have banned accumulators in state-regulated plans, but self-insured employer plans are exempt from state bans under ERISA.
What if nothing on this page fits my situation?
Licensed telehealth providers offer GLP-1 access at different price points. Some prescribe FDA-approved brand-name medications; others offer compounded options which are not FDA-approved. See the fallback section on this page or take our savings quiz.
How often is this page updated?
Monthly through 2026, then quarterly.
Still not sure which GLP-1 program is right for you?
You’ve seen the data. You know the programs exist. The question is which one fits your insurance, your drug, and your situation. Take our free 60-second matching quiz — we’ll ask your insurance type, state, income range, and medication, then give you a personalized savings plan with links to every program you qualify for.
Find My GLP-1 Savings Path →Check coverage on Ro — free, 2 minutes →Related guides
- Blue Cross Wegovy prior authorization — what each plan actually requires
- Best Wegovy providers that accept insurance in 2026
- Cheapest GLP-1 options without insurance — full pricing breakdown
- Foundayo (orforglipron) prior authorization guide
- Best compounded GLP-1 providers in 2026 — cash-pay options
- GLP-1 providers that accept Blue Cross — full comparison
- Orforglipron vs Retatrutide — 2026 data and verdict
- Best GLP-1 telehealth providers compared for 2026
The RX Index is a pricing intelligence and comparison resource for GLP-1 telehealth providers. This page contains affiliate links — we earn a commission if you sign up through our provider links. This does not affect which programs we recommend or how we present official manufacturer and government data. This page is not medical advice. All pricing and program terms are subject to change — verify on official program pages before making decisions.